BOSTON, Aug. 7, 2014 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced that it will host a conference call on Wednesday, August 13, 2014 at 4:30 p.m. ET to discuss the Company's financial results for its second quarter ended June 30, 2014, and provide an update on the Company.

Participants may access the call by dialing 844-824-7428 in the U.S. or 973-500-2177 outside the U.S. The call will also be webcast live on the Company's website at www.zafgen.com. A replay of this conference call will be available beginning at 7:30 p.m. ET on August 13, 2014 through August 20, 2014 by dialing 855-859-2056 in the U.S. or 404-537-3406 outside the U.S. Please provide Conference ID number 85806537.

About Zafgen, Inc.

Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity. Beloranib, Zafgen's lead product candidate, is a novel, first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in Prader-Willi syndrome, hypothalamic injury-associated obesity, including craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen was founded in 2005 to explore novel approaches to obesity therapeutics, including agents known to inhibit MetAP2 that had been found to drive unprecedented weight loss and metabolic improvements in mice. The Company is located in Boston, MA.

CONTACT: Investor Relations Contact:

         Brian Ritchie

         (212) 850-5683

         Brian.Ritchie@fticonsulting.com